UK revokes Valneva authorization for Ixchiq chikungunya vaccine
The UK Medicines and Healthcare products Regulatory Agency revoked Valneva's marketing authorization for its Ixchiq chikungunya vaccine after a benefit-risk review by the Commission on Human Medicines. Valneva said the action relied on existing safety information rather than a newly detected safety signal, and it leaves authorizations in other markets unchanged. The company will not challenge the decision and said the UK withdrawal should have minimal effect on sales because it had stopped actively supplying the market.
Why it matters
The withdrawal removes Ixchiq from the UK, but Valneva says the country had limited commercial significance and that it expects no recall expense. The company plans to concentrate Ixchiq access efforts on countries where chikungunya is endemic.
Key facts
- 1The UK regulator withdrew the marketing authorization for Ixchiq following a benefit-risk assessment by the Commission on Human Medicines. investing.com
- 2Valneva said the UK decision was based on previously available safety data rather than a newly identified safety signal. investing.com
- 3The withdrawal does not alter Ixchiq licenses in the European Union, Canada, Brazil, or other markets where it is sold. investing.com
- 4Valneva said it had not actively distributed Ixchiq in the UK for several months and that no doses remained there. investing.com
- 5Valneva said it will not appeal the UK decision. investing.com
- 6More than 61,000 people aged 18-59 years were vaccinated in a Brazilian pilot program, according to Valneva. investing.com
Open questions
- Reports of the immediate share-price response conflict: one material described a 6.5% decline, while another described a 2.4% gain.
Summary written by AlphAI from 11 of 11 sources. Not investment advice. Figures are as stated by the linked sources.